Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 3/20 | 0.34 |
| ▸ | LITAF | Q99732 | 3/20 | 0.34 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.33 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.33 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.33 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.33 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34466640 | 1.00 | SUV39H2 (0.37) | SUV39H2TLR9GRM5NSD2TNF | |
| SCHEMBL35210758 | 1.00 | SUV39H2 (0.37) | SUV39H2TLR9GRM5NSD2TNF | |
| SCHEMBL35211102 | 0.91 | TLR9 (0.35) | SUV39H2TLR9GRM5NSD2TNF | |
| SCHEMBL34466050 | 0.88 | GRM5 (0.34) | SUV39H2GRM5ALDH1A1MAP4K4STS | |
| SCHEMBL35212409 | 0.84 | CCR1 (0.33) | EHMT2MEN1KMT2A | |
| SCHEMBL35212060 | 0.84 | CCR1 (0.33) | EHMT2MEN1KMT2A | |
| SCHEMBL35212408 | 0.84 | CCR1 (0.33) | EHMT2MEN1KMT2A | |
| SCHEMBL35212553 | 0.84 | CCR1 (0.33) | EHMT2MEN1KMT2A | |
| SCHEMBL35211140 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL35210835 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | SUV39H2 4817/4885TLR9 3990/4885GRM5 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.